July 31, 2019
July 31, 2020
This CE activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.
Support for this activity has been provided through an educational grant from MedDay Pharmaceuticals.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
- Nurses — 1.5 contact hours (.5 in the area of pharmacology).
All other health care professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of neurologists, nursing professionals, pharmacists, PAs, rehabilitation specialists, mental health professionals, and other healthcare professionals who manage patients with MS.
An interactive activity that utilizes case studies to review the classification and management of progressive MS. New and emerging treatments are also discussed.
Upon completion of this activity, participants should be able to:
- Identify the subtypes of progressive MS, including “active” versus “non-active” disease course in patients with primary progressive or secondary progressive MS in order to personalize treatment
- Review the potential burden of disease associated with progressive forms of MS and the effects on the patients’ quality of life
- Employ strategies to plan for adaptations over time as disability increases
- Discuss current approaches to treatment and continued unmet needs for patients with non-active progressive MS
- Implement practical strategies for regular monitoring in patients with non-active disease
- Review the most recent information on treatment approaches in development for non-active progressive MS
Patricia Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Marie Namey, APRN, MSN, MSCN
Mellen Center for MS Treatment and Research
Edward Fox, MD, PhD
Director of the Multiple Sclerosis Clinic of Central Texas
Central Texas Neurology Consultants
Round Rock, TX
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The CMSC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for 1.5 contact hours of continuing nursing education (.5 in the area of pharmacology).
Disclosures of Conflicts of Interest
The following faculty report that they have relevant financial relationships to disclose:
Patricia Coyle, MD, FAAN, FANA
- Consultant: Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme, EMD Serono, and TG Therapeutics
- Contracted Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, and Novartis.
Marie Namey, APRN, MSN, MSCN
- Consultant: Biogen and Sanofi Genzyme
- Speakers Bureau: Biogen, EMD Serono, Genentech, and Sanofi Genzyme.
Edward Fox, MD, PhD
- Consultant: Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, and Teva
- Speakers Bureau: Acorda, Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, and Teva
- Contracted Research: Acorda, Biogen, Celgene, Chugai, EMD Serono, Genentech/Roche, Mallinckrodt, MedDay, Novartis, Opexa, Sanofi Genzyme, Teva, and TG Therapeutics.
Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, has declared that she has no relevant financial relationships to disclose.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.
The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
Method of Participation
There are no fees for participating and receiving CME/CE credit for this enduring activity. In order to receive credit, participants must read the CME/CE information and faculty disclosures, complete the pre-test questions, view the activity, answer the interactive questions throughout the activity, and complete the post-test and evaluation form. Statements of Credit are awarded upon successful completion of the post-test with a passing score of ≥ 70%, and evaluation form.
Certificates will be emailed to the participant
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For CME questions, please contact: Catamount Medical Education at: [email protected]
Catamount Medical Education, LLC, respects your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME/CNE credit. This information is provided to activity collaborators for the purposes of CME/CNE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information
For each visitor to this Web site, our Web server automatically recognizes information such as the visitor’s IP address. We use this information to allow participants to return and begin the activity at the place they last visited. We do not set any cookies on your computer. Catamount Medical Education, LLC, safeguards against the loss, misuse or alteration of information that we have collected in this activity.